HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Euro Results Round-Up: Alliance Pharma, Boiron And Ipsen

Executive Summary

Round-up of Q2 and H1 financial results from three Europe-based consumer health companies: Alliance Pharma, Ipsen and Boiron.

You may also be interested in...



Alliance Pharma Grows In US With Amberen Menopause Supplement

UK-based Alliance Pharma has strengthened its US offering by acquiring Biogix and its Amberen menopause supplement.

Ipsen Weighing Consumer Business Sale After Challenging 2020

Ipsen CEO David Loew has kicked off a strategic review of the company's "non core" Consumer Healthcare business, which has endured a particularly tough year thanks to the COVID-19 pandemic.

UK Industry Preparing Response To ‘Wide Ranging’ Medical Devices Consultation

UK consumer healthcare industry association PAGB is preparing its response to a "wide ranging" consultation on the future of how medical devices are regulated in the country. MHRA says it wants a system that streamlines product approvals while still prioritizing patient safety.

Topics

UsernamePublicRestriction

Register

RS151609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel